|
Azedra (iobenguane I 131) in patients with malignant, recurrent and/or unresectable pheochromocytoma or paraganglioma (PPGL): Updated efficacy and safety results from a multi-center, open-label, pivotal phase 2 study. |
|
|
Research Funding - Progenics (Inst) |
|
|
Research Funding - Progenics (Inst) |
|
|
Research Funding - Progenics (Inst) |
|
|
Research Funding - Progenics (Inst) |
|
|
Research Funding - Progenics (Inst) |
|
|
|
Stock and Other Ownership Interests - Progenics |
|
|
|
Stock and Other Ownership Interests - Progenics |
|
|
|
Stock and Other Ownership Interests - Progenics |
|
|
|
Stock and Other Ownership Interests - Progenics |
|
|
No Relationships to Disclose |
|
|
|
|
Stock and Other Ownership Interests - Progenics |
|
|
|
|
Stock and Other Ownership Interests - Progenics |
|
|
Research Funding - Progenics (Inst) |